Xbrane Biopharma Ab Stock Current Liabilities

Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.

In accordance with the recently published financial statements, Xbrane Biopharma AB has a Current Liabilities of 13 M. This is 99.26% lower than that of the Healthcare sector and 98.29% lower than that of the Drug Manufacturers - Specialty & Generic industry. The current liabilities for all Sweden stocks is 99.84% higher than that of the company.

The Macroaxis Fundamental Analysis modules help investors analyze Xbrane Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xbrane Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xbrane Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.